This hypothesis is currently being tested in a Phase 2 clinical trial (NCT04302025, www.clinicaltrials.gov, first posted 10 march 2020), which is evaluating responses to genotype-matched drugs in resectable NSCLC that carry ALK, ROS1, NTRK, BRAF, and RET driver mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.